在前性痴呆症和阿尔茨海默病的生存率
David Foxe1,2, James Muggleton1,3, Sau Chi Cheung1,2,4
1Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Neurodegenerative disease management
|July 2, 2025
概括
在前性痴呆症 (FTD) 和阿尔茨海默病 (AD) 亚型中,生存时间显著不同. 语义性痴呆症 (SD) 提供了最长的生存期,而逻辑性渐进性失语症 (LPA) 则是最短的. 临床因素影响预后.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 临床研究 临床研究
背景情况:
- 前性痴呆症 (FTD) 和阿尔茨海默病 (AD) 是不同的神经退行性疾病.
- 了解跨FTD亚型 (bvFTD,PNFA,SD) 和AD呈现 (记忆,LPA) 的生存率对于患者护理和研究至关重要.
- 在这些条件下影响生存的预后因素需要进一步阐明.
研究的目的:
- 为了比较行为变异前性痴呆症 (bvFTD),渐进性非流动性失语症 (PNFA),语义性痴呆症 (SD) 和逻辑开放性渐进性失语症 (LPA) 的定义良好的队列中生存时间.
- 为了评估典型 (无记忆) 的阿尔茨海默氏病 (AD) 与非典型 (无记忆) 的呈现相比,在典型 (无记忆) 的阿尔茨海默氏病 (AD) 中的生存率.
- 确定这些神经退行性疾病亚型中生存的人口和临床预测因素.
主要方法:
- 从321名参与者中收集了生存数据,包括54名bvFTD,26名PNFA,22名SD,20名LPA,32名AD和167名对照.
- 参与者接受了全面的基线评估和年度后续审查.
- 使用卡普兰-梅尔曲线和考克斯比例危险模型来分析生存数据.
主要成果:
- 平均存活时间有显著差异:SD (11.9年),LPA (7年),bvFTD (8.7年),PNFA (8.6年) 和AD (10年).
- 语义性痴呆症 (SD) 比PNFA和AD的存活时间显著长.
- 女性性别与LPA的生存时间较短有关;较短的症状持续时间,较低的认知能力和基线较差的功能结果与多个亚型的生存率降低有关.
结论:
- 对于不同的FTD和AD亚型,存在不同的生存轨迹.
- 人口特征和最初的临床表现为预测这些神经退行性疾病的生存率提供了有价值的预后信息.
- 这些发现有助于了解疾病的进展,并为临床管理策略提供信息.
相关概念视频
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Dementia
174
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
174
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Actuarial Approach
140
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
140
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458


